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Abstract
Objective—Primary sclerosing cholangitis (PSC) is a genetically complex, inflammatory bile 
duct disease of largely unknown aetiology often leading to liver transplantation or death. Little is 
known about the genetic contribution to the severity and progression of PSC. The aim of this study 
is to identify genetic variants associated with PSC disease progression and development of 
complications.
Design—We collected standardised PSC subphenotypes in a large cohort of 3402 patients with 
PSC. After quality control, we combined 130 422 single nucleotide polymorphisms of all patients
—obtained using the Illumina immunochip—with their disease subphenotypes. Using logistic 
regression and Cox proportional hazards models, we identified genetic variants associated with 
binary and time-to-event PSC subphenotypes.
Results—We identified genetic variant rs853974 to be associated with liver transplant-free 
survival (p=6.07×10−9). Kaplan-Meier survival analysis showed a 50.9% (95% CI 41.5% to 
59.5%) transplant-free survival for homozygous AA allele carriers of rs853974 compared with 
72.8% (95% CI 69.6% to 75.7%) for GG carriers at 10 years after PSC diagnosis. For the 
candidate gene in the region, RSPO3, we demonstrated expression in key liver-resident effector 
cells, such as human and murine cholangiocytes and human hepatic stellate cells.
Conclusion—We present a large international PSC cohort, and report genetic loci associated 
with PSC disease progression. For liver transplant-free survival, we identified a genome-wide 
significant signal and demonstrated expression of the candidate gene RSPO3 in key liver-resident 
effector cells. This warrants further assessments of the role of this potential key PSC modifier 
gene.
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Introduction
Primary sclerosing cholangitis (PSC) is a complex, cholestatic liver disease, in which 
chronic biliary inflammation and bile duct destruction leads to biliary fibrosis and liver 
cirrhosis, often in a slowly progressive manner.1 PSC is characterised by a cholangiographic 
image of strictures interchanged with dilatations throughout the biliary tract. Reported 
incidence rates of PSC vary widely, with incidence rates of 0.91, 1.31 and 0.5 per 100 000 
inhabitants per year for North America, Norway and the Netherlands, respectively.23 There 
is a male to female ratio of 2:1, and the disease can occur at any age, with a peak incidence 
around 40 years.3 There is a close association between PSC and IBD, and PSC patients are 
subject to a fivefold increased risk of developing colorectal carcinoma (CRC) when 
compared with the general population.3 In addition, PSC carries an excess risk of 
cholangiocarcinoma (CCA) which seems to be unrelated to the disease duration and the 
presence of liver cirrhosis.4 There is no effective medical therapy that can halt disease 
progression in PSC. The only curative option to date is liver transplantation.
The aetiology of PSC is still largely unknown. The aetiology is most likely to be 
multifactorial, in which the occurrence of PSC could be triggered by environmental factors 
in a genetic susceptible host.5 The relationship between susceptibility to PSC and 
environmental factors has been studied for several risk factors, of which smoking has 
repeatedly been shown to be associated with a decreased risk of developing PSC, 
independent of its protective effect in UC.6
Already in 1983, the identification of associations between PSC and HLA-B8 of the human 
leucocyte antigen (HLA) complex located on chromosome 6—harbouring several genes that 
are involved in antigen presentation and are important in immunity—raised interest in the 
role of genetics in PSC.7 This was amplified by a large Swedish study on PSC heritability 
demonstrated a nearly 4 to 17 times increased risk for first-degree relatives of patients with 
PSC to develop PSC when compared with the general population.8 The additional 3.3 times 
increased risk of UC and the presence of at least one concomitant immune-mediated disease 
outside the liver and bowel in approximately 20% to 25% of patients with PSC suggests a 
shared genetic component between these diseases.8–10 Over the last 5 years, the application 
of genome-wide association studies has resulted in an increasing insight in the genetic 
architecture of PSC, with the identification of 19 non-HLA risk loci at the time of writing.
11–14
Little is known about the genetic contribution to the severity and progression of complex 
diseases in general and PSC specifically. In Mendelian traits like cystic fibrosis and 
haemochromatosis, consortia efforts have led to the identification of robust and important 
modifier genes.1516 If genetic variants would be associated with PSC phenotypes, this could 
enable risk stratification of patients with PSC according to disease behaviour and would lead 
to insight into pathogenetic mechanisms associated to disease progression. While 
translational research from susceptibility genes has yet to prove useful for the development 
of new drugs in complex disease, modifier genes may point towards pathways involved in 
disease progression amenable by pharmacological interventions.
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The aim of this study is to identify genetic variants associated with PSC disease progression 
and development of complications, in a large, international, multicentre PSC cohort.
Methods
Study design and patients
Patients with PSC previously recruited throughout Europe, the USA and Canada and 
genotyped using the Immunochip by Liu et al13 were included. Subject recruitment was 
approved by the ethics committees or institutional review boards of all participating centres. 
Written informed consent was obtained from all participants. Patients of whom PSC 
diagnosis was revised after they were genotyped were excluded.
The following phenotypic data were collected for patient and disease characteristics: sex, 
date of birth, PSC subtype (small or large duct), date of PSC diagnosis, intrahepatic and/or 
extrahepatic disease, dominant strictures, concomitant IBD and type of IBD, date of IBD 
diagnosis and smoking status. Furthermore, follow-up data were collected for date and cause 
of death, date and indication of liver transplantation, occurrence and date of diagnosis of 
hepatocellular carcinoma (HCC), CCA, CRC, gallbladder carcinoma and occurrence and 
date of a colectomy.
PSC diagnosis was based on clinical, biochemical, cholangiographic and histological 
criteria, as formulated by the European Association for the Study of the Liver guidelines.17 
IBD diagnosis was scored based on accepted endoscopic, radiological and histological 
criteria.18
PSC-related death was defined as death from liver failure, death from cholangiosepsis, death 
from CCA or death from gallbladder carcinoma. The time-to-event phenotype liver 
transplant-free survival was defined as the time between PSC diagnosis and the composite 
endpoint of either liver transplantation or PSC-related death.
We used genotype data of patients with PSC as previously described.13 Online 
supplementary appendix 1 describes the quality control applied to this dataset. A total of 130 
422 single nucleotide polymorphisms (SNPs) for 3402 PSC samples remained after quality 
control and were used in the analysis.
Statistical analysis
The age at PSC diagnosis was expressed as median value and IQR. Categorical variables 
were expressed as numbers and percentages based on non-missing values.
Binary associations—Binary associations were calculated using multiple logistic 
regression. We corrected for clinical covariates by adding them to the regression model. To 
determine which clinical covariates to correct for, we performed a backward elimination 
procedure per binary phenotype. We started with the full model including sex, country, date 
of PSC diagnosis, established IBD diagnosis and smoking status and removed covariates 
from the model until the Akaike information criterion stabilised.
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Time-to-event associations—Cox proportional hazards regression was used to estimate 
the effect of genetic variants on time-to-event PSC subphenotypes. Clinical variables that 
were significantly associated with the time-to-event phenotype in univariable Cox regression 
analyses (p<0.05) were entered into a multivariable Cox model alongside the genotype. To 
visualise the effect of genotype on time-to-event phenotypes, Kaplan-Meier survival 
estimates were plotted (see methods described in online supplementary appendix 1).
We used the SNP2HLA software19 to impute classical HLA alleles from genotype data for 
HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-DPA1 and HLA-
DPB1 and their corresponding amino acid polymorphisms from the genotype data (methods 
described in online supplementary appendix 1).
Mouse experiments and in vitro experiments on the role of RSPO3 in PSC
Mouse experiments—C57BL/6 (B6) mice were purchased from Charles River (Milan, 
Italy). Normal C57BL/6 mice were sacrificed at the age of 8–10 weeks. Organs were 
harvested and washed by cold phosphate buffered saline. Cholangiocytes were isolated both 
from normal mice (n=3) and from mice (n=3) fed 0.1% 3,5-diethoxycarbonyl-1,4-
dihydrocollidine (DDC) for 4 weeks, as a model of sclerosing cholangitis.20 Total RNA was 
extracted and sequenced on an Illumina HiSeq 2000 machine (see online supplementary 
appendix 1 for more details).
In vitro experiments on human primary biliary tissue, cholangiocyte-like cells 
and hepatic stellate cells—Human primary biliary tissue was obtained from a liver and 
pancreas organ donor after obtaining informed consent from the donor's family. A section of 
the bile duct was excised and homogenised and RNA was extracted. Cholangiocyte-like cells 
(CLCs) were generated from human induced pluripotent stem cells and cultured. RSPO3 
expression was determined using quantitative PCR (qPCR) and compared with the 
housekeeping gene using the 2−ΔCt method.21 Next to that, we used previously published 
microarray data to verify RSPO3 expression.22 The R/Bioconductor package limma23 was 
used to evaluate differential expression between pairs of conditions (human-induced 
pluripotent stem cells (hIPSCs) and CLCs and hIPSCs and primary bile duct). A linear 
model fit was applied and p values were corrected using the method of Benjamini and 
Hochberg.24 Methods are further described in online supplementary appendix 1.
Primary human hepatic stellate cells were isolated and cultured from wedge sections of liver 
tissue, obtained from patients undergoing surgery at the Royal Free Hospital in London. 
Total RNA was extracted and retrotranscribed into complementary DNA, which was used 
for gene expression assessment with qPCR. Gene expression was compared with the 
housekeeping gene using the 2−ΔCt method.
Results
Patient characteristics and natural history
Clinical characteristics of the PSC cohort are described in table 1. The cohort consisted of 
2881 patients from Europe and 521 patients from the USA and Canada (see online 
supplementary table 1). A total of 2185 (65%) patients were male, and the median age at 
Alberts et al. Page 4
Gut. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
PSC diagnosis was 38.6 years (IQR 28.0–50.1). Concomitant IBD was diagnosed in 2390 
(75%) patients. The median follow-up was 8.7 years. In total, 874 (26%) patients underwent 
liver transplantation and 181 (5%) patients died of PSC-related causes. Over 11% of patients 
developed a malignancy, most often CCA (5.6%) or CRC (4.3%).
Genetic associations with binary subphenotypes
Genome-wide association analyses focusing on the occurrence of malignancy in patients 
with PSC revealed several suggestive associations (see online supplementary table 2). When 
comparing 107 patients with PSC autoimmune hepatitis (AIH) with 3159 patients with PSC 
but without AIH overlap, a strong genetic association in the HLA-DQB1 gene was identified 
(top SNP rs3891175, p=4.6×10−11, OR=2.41). After imputation of the classical HLA alleles, 
we found that the alleles DQA1*05:01 and DQB1*02:01 were most significantly associated 
with PSC/AIH overlap (p values of 3.8×10−11 and 1.8×10−07). For other binary 
subphenotypes—small duct PSC, the occurrence of HCC, gallbladder carcinoma and 
proctocolectomy—no genetic associations were found.
Genetic associations with time-to-event subphenotypes
Next, we aimed to determine whether genetic variants are associated with important time-to-
event variables reflecting the PSC disease course, for example, time between PSC diagnosis 
and the development of a carcinoma. For this, we developed a framework to perform 
immunochip-wide Cox proportional hazards analyses. We defined the liver transplant-free 
survival subphenotype as time from PSC diagnosis until liver transplantation or PSC-related 
death.
Univariable Cox regression analyses including clinical parameters showed statistically 
significant associations with the time to event endpoint transplant-free survival for sex, 
country, date of PSC diagnosis, established IBD diagnosis and smoking status. Next, we 
tested 130 422 SNPs for association with liver transplant-free survival using multivariable 
Cox proportional hazards regression, including the genotype effect alongside the significant 
clinical covariables. We found SNP rs853974 to be associated with liver transplant-free 
survival of patients with PSC at genome-wide significance (p=6.07×10−9). Kaplan-Meier 
survival analysis showed a 50.9% (95% CI 41.5% to 59.5%) transplant-free survival for 
homozygous AA allele carriers of rs853974 compared with 72.8% (95% CI 69.6% to 
75.7%) for GG carriers at 10 years after PSC diagnosis (figure 1A). AA homozygotes had a 
2.14 (95% CI 1.66 to 2.76) increased hazard, indicating a 2.14 larger relative risk for need 
for liver transplantation or for PSC-related death compared with GG homozygotes. Figure 
1B shows a regional plot of this observed association.
SNP rs853974 is located on chromosome 6. We did not identify a direct functional effect of 
this SNP on gene expression or regulatory features (see online supplementary appendix 1). 
We hypothesised that neighbouring gene R-Spondin 3 (RSPO3) would be the most likely 
positional candidate gene. The other neighbouring gene, CENPW, has a fundamental role in 
kinetochore assembly and is required for normal chromosome organisation and progress 
through mitosis and thtaberefore not a good candidate. In addition to SNP rs853974, 
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additional suggestive genetic associations with time-to-event phenotypes liver transplant-
free survival and time to CCA were found (see online supplementary table 3).
Expression of RSPO3 in key liver-resident effector cells
To assess whether RSPO3 is expressed in disease-relevant cells (cholangiocytes and hepatic 
stellate cells), we performed RNA sequencing on healthy and cholestatic cholangiocytes and 
multiple organs derived from normal C57BL/6 mice. RSPO3 expression was 7 to 20 folds 
higher in cholangiocytes as compared with any of the organs. Furthermore, RSPO3 
expression was higher in healthy cholangiocytes than in cholestatic cholangiocytes (figure 
2A).
Next, using microarrays, we assessed expression of RSPO3 in hIPSCs, hIPSC-derived 
CLCs, and human PBD samples. RSPO3 expression was significantly higher in CLCs and 
PBD cells compared with hIPSCs (figure 2B). This finding was confirmed by qPCR (figure 
2C).
Since activated hepatic stellate cells are the main cells involved in liver fibrosis,25 we also 
investigated expression of RSPO3 in human culture-activated hepatic stellate cells. We 
isolated, cultured and activated human hepatic stellate cells of three patients without PSC. 
Using qPCR, we observed expression of the hepatic stellate cell marker gene cytoglobin B, 
as well as expression of RSPO3 in all three subjects (figure 2D). We did not observe RSPO3 
expression in human CD4 and CD8 T lymphocytes (data not shown).
Discussion
To date, very few disease-modifying genes have been identified in rare complex diseases. 
Collaboration within the international PSC study group enabled the establishment of a 
cohort of unprecedented size, for an orphan disease such as PSC, enabling the investigation 
of genetic variation underlying the progression of PSC through time. Overall, it is a major 
challenge to determine genetic variants associated with survival, and only few genetic 
studies investigating this have been published.26 We present a conceptually new method to 
determine associations between genetic variants and disease course, using genome-wide 
multivariable Cox proportional hazards regression analyses. Here, we identify a genome-
wide significant association between SNP rs853974 —located close to the RSPO3 gene—
and liver transplant-free survival in PSC. Interestingly, this locus is not associated with PSC 
susceptibility and thus exemplifies different genetic regulation of disease susceptibility and 
disease progression.
This study is based on genotype data obtained using Illumina immunochip, a genotyping 
platform that densely covers genetic regions associated to immune-mediated diseases. Use 
of genome-wide association study (GWAS) arrays, that more uniformly cover genetic 
variants all over the genome, would have been ideal. However, a complete GWAS dataset for 
the entire international cohort was not available at the time of study. For that reason, we 
started with the available immunochip data. Given the positive findings in this study, a 
similar study on GWAS arrays data could very well be of additional value.
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For the binary phenotype of developing CCA or not, we found an association at 
chromosome 5 at 150 Mb (see online supplementary table 2). Of interest, this locus contains 
an established genetic association with Crohn’s disease susceptibility in the autophagy gene 
IRGM.27 For the phenotype of developing colorectal carcinoma or not, we found an 
association at chromosome 14 at 35 Mb. This locus appeared not to be associated with 
sporadic colorectal cancer.
Since transplant-free survival is a combined and heterogeneous phenotype, we assessed to 
which extent the following three subgroups contribute to the association:
(1) transplanted patients with indication for transplantation ‘end stage liver disease’ and 
patients died because of ‘liver failure’; (2) transplanted patients with indication for 
transplantation ‘cholangiocarcinoma (cca)/high-grade dysplasia’ and patients died because 
of ‘cca or gallbladder carcinoma’ and (3) transplanted patients with indication for 
transplantation ‘intolerable complaints/pruritus/recurrent cholangitis’ and patients died of 
‘cholangiosepsis’. We observed a stronger contribution of subgroups 1 and 3 to the 
association, indicating that the underlying biological mechanism is more likely one involved 
in causing progression of liver disease and/or cholangitis or cholangiosepsis rather than a 
mechanism involved in cancer development.
RSPO3 is a member of the R-Spondin protein family (R-Spondin 1–4).28 These proteins are 
secreted agonists of the canonical Wnt/beta (β)-catenin signalling pathway.28 They activate 
the pathway leading to induced transcription of Wnt target genes. Wnt/β-catenin signalling 
plays a central role in embryogenesis, organogenesis and adult homeostasis and is a critical 
regulator of stem cell maintenance.2930 RSPO3 is a ligand of the Frizzled 8 and LRP5/6 
receptors.28 In the canonical form of the Wnt pathway, binding of ligands to the Frizzled 
receptor and LRP5 or 6 coreceptors causes β-catenin to dephosphorylate in the cytoplasm. 
Accumulated β-catenin translocates to the nucleus where it binds to T cell factor/Lymphoid 
enhancer-binding factor, causing transcription of Wnt target genes—such as Fibronectin, 
MMP-7, Twist and Snail. These factors activate hepatic stellate cells and induce liver 
fibrosis. Blocking the Wnt signalling pathway using Dickkopf-1, a Wnt coreceptor 
antagonist, restores hepatic stellate cells quiescence in culture.31 Hence, Wnt signalling is 
involved in both progression and regression of liver fibrosis, either by inhibiting or 
promoting activation and survival of hepatic stellate cells.3132 Also, RSPOs have been 
shown to facilitate hepatic stellate cell activation and promote hepatic fibrogenesis.33 Here, 
we demonstrate that RSPO3 is expressed in key effector cells involved in the pathogenesis of 
PSC. Since we have shown that patients with PSC that are homozygote AA carriers of 
rs853974 progress more rapidly towards PSC-related death or liver transplantation, RSPO3 
can be regarded a plausible candidate gene to be involved in PSC disease progression. 
Hypothetically, patients with PSC might benefit from reduction of RSPO3 or generally 
canonical Wnt signalling.
In an immunochip analysis of the International IBD Genetics Consortium including over 75 
000 individuals,34 an intronic SNP rs9491697 in RSPO3 (which is not in linkage 
disequilibrium with rs853974, r2=0.014) was identified to be associated with Crohn’s 
disease (p=3.79×10−10, OR=1.077) but not with UC. Given the small number of patients 
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with Crohn’s disease (n=357) within the present study, the lack of linkage disequilibrium 
between the two ‘hit SNPs’ and the fact that our multivariate Cox model corrected for IBD-
status, the identified association signal does not seem to be driven by the co-occurrence of 
Crohn’s disease in our cohort.
For several binary and time-to-event subphenotypes, we found suggestive genetic 
associations. Two additional SNPs, rs1532244 on chromosome 3 and rs17649817 on 
chromosome 5, were suggestively associated with transplant-free survival. Furthermore, one 
SNP, rs7731017, was suggestively associated with the presence of CCA. We investigated 
whether any of the candidate genes in the locus overlapped with genes identified in tumour 
sequencing studies of CCA. We did not find an overlap with the 32 genes reported to be 
significantly altered in intrahepatic, extrahepatic and gallbladder cancer by Nakamura et al.
35
 When comparing the genes in our CCA locus with 1146 genes containing non-
synonymous somatic mutations in intrahepatic CCA,36 we found that the SYNPO gene was 
both in the list of 1146 genes of the sequencing study as well as in the locus that we 
identified to be associated with the presence of CCA. There is little known about this gene 
and there is no connection with oncogenesis. Another gene, SP100, was found in this study 
to be in the locus associated with time to CCA and is also in the list of 1146 genes. SP100 is 
associated with autoimmune disease of the urogenital tract and also with PBC. Interestingly, 
anti-sp100 autoantibodies have been described for PBC.37 The genetic association of SP100 
with both PBC and the time to CCA within patients with PSC as well as the existence of 
anti-sp100 autoantibodies makes this an interesting gene for future follow-up studies.
When comparing patients with PSC-AIH with patients with PSC but without AIH, we found 
a strong genetic association with PSC-AIH in the HLA-DQB1 gene. The identified variant 
was tagging the classical HLA haplotypes DQA1*05:01 and DQB1*02:01. These 
associations overlap the associations found by a previous genome-wide association study of 
AIH type 1 in the Netherlands,38 suggesting that the genetic basis for AIH type 1 
pathogenesis is similar for patients with isolated AIH type 1 compared with patients with 
PSC-AIH.
This study is limited by the relatively small cohort size when compared with other GWAS 
studies that incorporate tens of thousands of samples. The resulting lack of statistical power 
may have played a role in the binary analyses, in which suggestive hits were found for CCA 
and CRC but genome-wide significance was not reached. However, PSC is a rare disease, 
and the present study has included patients recruited throughout the world in a joined effort. 
It is therefore not expected that a larger cohort of PSC cases will become available soon.
In conclusion, we present the largest association study of PSC genotypes with disease 
phenotypes to date. We identified several genetic variants associated with PSC disease 
course. Specifically, we report rs853974 to be genome-wide significantly associated with 
liver transplant-free survival in PSC. Findings of candidate gene RSPO3 being expressed in 
both mouse and human cholangiocytes and human-activated hepatic stellate cells warrant 
further assessments of the role of this potential key PSC modifier gene.
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Significance of this study
What is already known on this subject?
► Several case–control genome-wide association studies have revealed 20 
susceptibility loci for primary sclerosing cholangitis.
► Little is known about the genetic contribution to the severity and progression 
of complex diseases in general and primary sclerosing cholangitis in 
particular.
► RSPO3 plays a role in the activation of the canonical Wnt signalling pathway, 
which is involved in liver fibrosis.
What are the new findings?
► The genetic variant rs853974 is genome-wide significantly associated with 
liver transplant-free survival in primary sclerosing cholangitis.
► Candidate gene RSPO3 is expressed in both murine and human 
cholangiocytes and in human hepatic stellate cells.
► Three new loci were found to be associated with time to cholangiocarcinoma 
in patients with primary sclerosing cholangitis.
How might it impact on clinical practice in the foreseeable future?
► Through its effect on liver fibrosis, RSPO3 could play an important role in 
PSC disease progression, and insight in its mechanism could lead to new 
therapeutic targets.
► Furthermore, since we demonstrated that genetic variants are associated with 
PSC disease progression, genetics could provide a tool for risk stratification 
of patients with PSC in the future.
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Figure 1. 
Association of genetic variants on chromosome 6 with transplant-free survival of patients 
with PSC. (A) Kaplan-Meier curves of transplant-free survival. Patients are stratified 
according to their genotype for SNP rs853974. The p value for genotype effect in the Cox 
proportional hazards model is p=6.07.10−09. (B) Regional association plot for transplant-free 
survival. The Y-axis shows the −log10(p value) for genotype effect in the Cox proportional 
hazards model. PSC, primary sclerosing cholangitis; SNP, single nucleotide polymorphism.
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Figure 2. 
RSPO3 expression in mouse cholangiocytes and in human CLCs, PBD and HSCs. (A) RNA 
sequencing analysis of RSPO3 expression in DDC-induced cholestatic cholangiocytes, 
healthy cholangiocytes and multiple organs of normal C57BL/6 mice. (B) Microarray 
RSPO3 expression in hiPSCs, CLCs and PBD. RSPO3 expression is significantly increased 
in CLCs and in PBD compared with hiPSCs. n=3; error bars, SD. Asterisks represent 
statistical significance (****adjusted p<0.0001, ***adjusted p<0.001, Benjamini and 
Hochberg corrected p values). (C) Quantitative real-time PCR analysis demonstrating the 
expression of RSPO3 in hiPSC-derived CLCs and PBD samples compared with expression 
in hiPSCs. Expression levels are fold changes compared with housekeeping gene HMDS 
calculated using the 2−ΔCt method. (D) Quantitative real-time PCR analysis showing 
expression of RSPO3 and cytoglobin B in three patients without PSC. Cytoglobin B 
messenger RNA expression was evaluated as specific HSC marker. Target genes were 
normalised using GAPDH as endogenous control and their relative expression was 
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calculated with the 2−ΔCt method. CLCs, cholangiocyte-like-cells; DDC, 3,5-
diethoxycarbonyl-1,4-dihydrocollidine; FPKM, fragments per kilobase of exon per million 
mapped reads; hIPSC, human-induced pluripotent stem cells; HSC, hepatic stellate cell; 
PBD, primary bile duct.
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Table 1
Clinical characteristics of the PSC cohort consisting of 3402 patients
Variable Groups Number (%)
Age at PSC diagnosis* 38.6 years old (28.0–50.1)
Sex Male 2185 (64.7)
Female 1193 (35.3)
Missing 24 (0.7)
Main diagnosis PSC 3159 (94.6)
Small duct PSC 75 (2.2)
PSC with AIH overlap 107 (3.2)
Missing 61 (1.8)
Liver transplantation Yes 874 (26.3)
No 2444 (73.7)
Missing 84 (2.5)
Colectomy Yes 419 (12.6)
No 2897 (87.4)
missing 86 (2.5)
IBD No IBD 816 (25.5)
Ulcerative colitis 1940 (60.5)
Crohn's disease 357 (11.1)
IBD-U 93 (2.9)
Missing 196 (5.8)
Cholangiocarcinoma Yes 188 (5.6)
No 3147 (94.4)
Missing 67 (2.0)
Colorectal carcinoma Yes 127 (4.3)
No 2822 (95.7)
Missing 453 (13.3)
Gall bladder carcinoma Yes 30 (1.0)
No 2977 (99.0)
Missing 395 (11.6)
Hepatocellular carcinoma Yes 22 (0.7)
No 2984 (99.3)
Missing 396 (11.6)
Smoking status Smoker 140 (6.0)
Ex-smoker 529 (22.7)
Non-smoker 1657 (71.2)
Missing 1076 (31.6)
Death Non-PSC related 47 (1.5)
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Variable Groups Number (%)
Liver failure 66 (2.1)
Cholangiosepsis 18 (0.6)
Gallbladder carcinoma 12 (0.4)
Cholangiocarcinoma 85 (2.6)
Hepatocellular carcinoma 6 (0.2)
Colorectal carcinoma in case of coexisting IBD 3 (0.1)
Alive 2977 (92.6)
Missing 188 (5.5)
Quantitative data are expressed as counts and percentages excluding missing data.
*Values shown as median (IQR).
AIH, autoimmune hepatitis; IBD-U, inflammatory bowel disease unclassified; PSC, primary sclerosing cholangitis.
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